

## CURRENT REPORT

Report date: **30.09.2026**

Name of issuing company: **Antibiotice S.A.**

Headquarters: **Iași, str. Valea Lupului nr. 1, zip code 707410**

**<https://www.antibiotice.ro>**

E-mail: **[relatiicuinvestitorii@antibiotice.ro](mailto:relatiicuinvestitorii@antibiotice.ro)**

Telephone/fax no. : **+40232 209 000 / +40372 065 633**

Unique registration code in the Trade Register Office: **R01973096**

No. in the Trade Register: **J1991000285223**

Subscribed and paid-up capital: **67,133,804 LEI**

The regulated market trading on which the securities are issued: **Bucharest Stock Exchange**

Number of shares: **671,338,040**

Number of votes: **671,338,040**

Main characteristics of the securities issued by the company: **nominative shares, nominal value: 0.10 lei**

### **Resolutions of the Ordinary General Meeting of Shareholders**

The General Meeting of Shareholders of Antibiotice S.A., a trading company established and operating according to the Romanian law, registered at the Trade Register Office Iasi attached to the Court of Iasi, under the no. **J1991000285223**, unique registration code R01973096, headquartered in 1 Valea Lupului St., Iasi, Romania, having subscribed and paid-up capital in the amount of 67,133,804 LEI divided in 671,338,040 ordinary registered shares, with a nominal value of 0.10 lei each,

*convened* by the announcement published in the Official Gazette of Romania, Part IV, no. 5815/19.08.2026 and in Evenimentul no. 10767 dated on 19.08.2026,

*according to* the provisions of Law no. 31/1990 on trading companies, republished, with the subsequent amendments and completions, Law no. 24/2017 on issuers of financial instruments and market operations, republished, FSA Regulation no. 5/2018 on issuers of financial instruments and market operations, with the subsequent amendments and completions, Government Emergency Ordinance no. 109/2011 on corporate governance of public enterprises and provisions of the company's Articles of Association,

*convened on 30.09.2026*, at 10 a.m., for an Ordinary Meeting at Antibiotice headquarters, for the first reunion, gathering shareholders representing 53.0175% of the share capital, respectively 53.0175% of the total no. of voting rights, statutory and legally constituted,

*following the debates,*

### **DECIDES:**

**Resolution no.1:** With the " in favour " votes of the shareholders representing 100% of the total votes cast, the General Meeting of Shareholders approves the Financial Report for the first half of 2026, consisting of:

- a. simplified half-yearly financial statements;
- b. half-yearly report of the board of directors;
- c. the declaration of the responsible persons;

- d. the full report of the audit firm.

**Resolution no.2:** With the "against" votes of the shareholders representing 88.5931% of the total votes cast, the General Meeting of Shareholders does not approve the allocation of 50% of the net profit for the 2025 financial year, setting the gross dividend at RON 0.019877174 per share, setting 16 October 2026 as the record date for identifying the shareholders entitled to the effects of this resolution, setting 15 October 2026 as the ex-date, and setting 28 October 2026 as the dividend payment commencement date.

**Resolution no.3:** With the "in favour" votes of the shareholders representing 90.5607% of the total votes cast, the General Meeting of Shareholders approves the allocation of 90% of the net profit for the 2025 financial year, setting the gross dividend at RON 0.035778913 per share, setting 16 October 2026 as the record date for identifying the shareholders entitled to the effects of this resolution, setting 15 October 2026 as the ex-date, and setting 28 October 2026 as the dividend payment commencement date.

**Resolution no.4:** With the "in favour" votes of the shareholders representing 99.1347% of the total votes cast, the General Meeting of Shareholders approves the ratification of the Management Board's Decision no. 1 of 25.06.2026, regarding:

- the approval of the increase in the multicurrency, multiproduct, cash and non-cash credit facility, contracted with UniCredit Bank SA from the amount of RON 91,500,000 to the amount of RON 141,000,000.
- the approval/maintenance of the guarantee of the facility mentioned above, in the amount of RON 141,000,000, which will be contracted with UniCredit Bank SA with the following:
  - Mortgage on the current and future accounts opened by Antibiotice SA at UniCredit Bank SA.
- approval of the authorization of Mr. Ioan Nani as General Director to sign on behalf of Antibiotice SA all documents/credit contracts and their accessories, necessary and related to the contracting and implementation of the credit facility in the total amount of RON 141,000,000 from UniCredit Bank SA, as well as all the subsequent additional documents related to the documents/credit contracts and accessories related to this credit.

**Resolution no.5:** With the "in favour" votes of the shareholders representing 100% of the total votes cast, the General Meeting of Shareholders approves the rectification of the Decision no. 3 of the Ordinary General Meeting of Shareholders dated 06.11.2025, in order to remedy a material error, as follows:

Resolution No. 3 of the Ordinary General Meeting of Shareholders dated November 6, 2025—stating "With the votes 'for' from shareholders representing 100% of the total votes cast, the vacancy of a director position at Antibiotice S.A. is acknowledged"—is rectified to read: "With the votes 'for' from shareholders representing 100% of the total votes cast, the vacancy of the director position held by Mr. Cătălin-Codruț Popescu is acknowledged, effective as of November 6, 2025."

The President of the Management Board, Mr. Ionut Sebastian IAVOR, declare that the decisions of this General Meeting of Shareholders have been validly signed and that the legal representatives of the shareholders (the proxies) have been authorized and have met all legal and statutory conditions to represent the shareholders who gave them mandates (the principals).

These decisions are signed today **30.09.2026**.

President of the Management Board,  
Ionut-Sebastian IAVOR